European Psychiatry - Volume 33 - March 2016

310 / 812

S306 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW541
Quality of Life Assessment in
schizophrenia - development of a
short version of the QLiS
M. Franz ∗ enin eyer
1 Vitos Klinik Kurhessen, Vitos Klinik Kurhessen, Bad Emstal, Germany
2 Institute of epidemiology- social medicine and health services
research, Integrative rehabilitation research unit, Hannover, Germany
∗ Corresponding author.
The QLiS (Quality of Life in Schizophrenia) is a disease-specific
questionnaire with high content validity and sound psychometric
properties. It comprises 54 items related to 12 subscales. However,
its use in surveys or clinical studies is limited due to its length. Our
aim was to develop and validate a short form of the QLiS.
Four steps were taken to develop the short form (QLiS-SF) using
samples from the Clinical Analysis of the Treatment of Schizophre-
nia study. 1. Amodel with second order scales was developed using
exploratory factor analysis. 2. The resulting model was tested in
an independent sample using confirmative factor analysis (CFA).
3. Based on this model, items were selected on grounds of dis-
tributional properties, content reviews, and item loadings. 4. The
resulting short form was validated independently through CFA.
Results Three second order scales were constructed: illness-
related quality of life, social life, and global subjective well-being.
CFA of the new theoretical model resulted in a CFI of 0.67 and abso-
lute fit indices of CMIN/df = 2.55, RMSEA = 0.08, SRMR = 0.09. We
selected 13 items that showed good statistical properties and good
fit of content to subscale. Fit of the underlying theoretical model
with the 13 items was satisfactory (CFI = 0.95, CMIN/df = 2.23,
RMSEA = 0.06, SRMR = 0.04). Composite reliability scores for the
three subscales were above 0.70.
The QLiS-SF showed adequate model fit and reliability. It offers a
novel, well-founded opportunity to assess quality of life in persons
with schizophrenia in situations in which the application of the
long version is not considered possible.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW542
The relationship between childhood
trauma and theory of mind in
schizophrenia
J. Mrizak ∗, R. Trabelsi , A. Arous , A. Aissa , H. Ben Ammar ,
Z. El Hechmi
Razi Hospital, Psychiatry F, Mannouba, Tunisia
∗ Corresponding author.
Introduction A history of childhood trauma is reportedly more
prevalent in people suffering from psychosis than in the gen-
eral population. Previous studies linked childhood trauma (CT) to
neurocognitive impairments in schizophrenia (SCZ), but rarely to
theory of mind (TOM) deficits.
Objectives To investigate the relationship between TOM deficits
and CT in SCZ.
Methods Fifty-eight outpatients with stable SCZ completed the
Childhood Trauma Questionnaire retrospectively assessing five
types of childhood trauma (emotional, physical and sexual abuse,
and emotional and physical neglect). They also completed an
intention-inferencing task, inwhich the ability to infer a character’s
intentions from information in a short story is assessed.
Results Our results suggest a relationship between specific kinds
of CT and TOM deficits. A history of childhood physical neglect was
significantly correlated to a worse performance in the intention-
inferencing task (P = 0,001). Patients with higher scores of CT denial
also had less correct answers (P = 0,035) and more false answers
(P = 0,013).
Conclusions Our results need replication but underline the neces-
sity of investigating psychosocial mechanisms underlying the
development of social cognition deficits, including deficits in TOM.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW543
Prevalence and predictors of the
metabolic syndrome in patients on
the long term atypical antipsychotic
treatment
I. Popovic ∗, S. Ðukic - Dejanovic , V. Popovic , S. Vladejic
1 Specialized Psychiatric Hospital “Gornja Toponica”, Admission
Ward, Gornja Toponica- Niˇs, Serbia
2 Faculty of Medical Sciencies- Kragujevac, Psychiatry, Kragujevac,
Serbia
3 Specialized Psychiatric Hospital “Gornja Toponica”, Addiction Ward,
Gornja Toponica- Niˇs, Serbia
4 Specialized Psychiatric Hospital “Gornja Toponica”, Forensic Ward,
Gornja Toponica- Niˇs, Serbia
∗ Corresponding author.
Objective We performed a case-control clinical study, which
included 285 long term hospitalized schizophrenic patients, both
gender, treatedwithmonotherapy clozapine, olanzapine or risperi-
done for at least 6 months. Patients with diagnosed metabolic
syndrome according to International Diabetes Federation (IDF)
criteria were classified as cases, while the “controls” were patients
treated with the same antipsychotic drug without the metabolic
syndrome presence. The aim of this research was to determine the
correlation of the studied variables as a potentially risk factors for
the metabolic syndrome presence.
Materials and methods The following variables were collected:
basic physical parameters (height, weight, waist circumference,
blood pressure), clinical status (BPRS scale and PANSS scale for
schizophrenia), laboratory data (fasting glucose level, serum lipid
levels, C-reactive protein, microalbuminuria), and medical-record
data.
Results General prevalence of metabolic syndrome was 31,2%,
in patients treated with clozapine 41,3%, olanzapine 34,4% and
risperidone 19%, statistically significant clozapine vs. risperidone
(P < 0.05). Predictors of the metabolic syndrome computed by mul-
tivariate logistic regression: - patients treated with olanzapine:
case-history data about diabetes mellitus in close family mem-
ber (OR 14.134, 95% CI 2.724–73.348, P = 0.002); hyperlipidemia
in close family member- (OR 53.134, 95% CI 2.768–1019.916,
P = 0.008; BMI [kg/m2] - (OR 1.328, 95% CI 1.105–1.597, P = 0.002);
C-reactive protein over the cutoff point of 5 mg/L (OR 4.555,
95% CI 1.057–19.627, P = 0.042), and mankind (OR 4.653, 95% CI
1.008–21.479, P= 0.049); patients treated with clozapine: diabetes
mellitus in close family member (OR 14.127, 95% CI 2.407–82892,
P = 0.003); patients treated with risperidone - there were no signif-
icant predictors.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.